SPECIAL SEMINAR - Centre De Lutte COntre Le Cancer Eugène Marquis

“Translational research in pancreatic adenocarcinoma: towards a better understanding of the mechanisms of resistance to therapies and a rationalization of the introduction of PARP inhibitors”

Anthony TURPIN, Medical Oncologist, Doctor of Science, University lecturer-Practitioner - LILLE UNIVERSITY HOSPITAL

and

Audrey VINCENT, INSERM Project Leader, Scientific leader of the 3D organoid core facility, OrgaRES - LILLE UNIVERSITY

UMR 9020 CNRS - UMR 1277 INSERM

CANcer Heterogeneity, Plasticity an dResistance to THERapies (CANTHER) LILLE

Research Team: “Mucins, Cancer and Drug Resistance”

Abstract
Pancreatic ductal adenocarcinoma (PDAC) ranks as the 5th leading cause of cancer death in Western countries. Recent therapeutic advances have yielded limited success, necessitating more personalized treatment protocols based on tumour molecular and functional characteristics. Our recent work allowed us to establish an original model of pancreatic patient-derived tumor organoids (PDTO) treated with the FOLFIRINOX regimen, revealing critical time points in the acquisition of chemoresistance to this combination of drugs and potentially new opportunities for targeted therapies such as PARP inhibitors. The use of PDTO models in general could lead to new treatment strategies for a significant proportion of patients, offering potential alternative sequences through guided second-line treatment decisions.